Infectex, Ltd is a private biotechnology company founded in 2011 with the goal to develop and bring to the Russian market an innovative drug for the multidrug-resistant tuberculosis (MDR-TB) treatment. Infectex has been financed by Maxwell Biotech Venture Fund, is Skolkovo resident and takes part in Technology platform “Medicine of the Future”. Projected product (SQ109) - worldwide rights owned by “Sequella Ltd” - is a low-molecular ethylene diamine compounds, some compounds of this family are used in the first-line treatment of tuberculosis (e.g., ethambutol). In 2010 Thomson Reuters Pharma™ rating agency included SQ109 in the top five most promising drugs that are in Phase II clinical studies.
View Top Employees from Infectex| Website | http://www.infectex.ru |
| Revenue | $1 million |
| Employees | View employees |
| Founded | 2011 |
| Address | Radishchevskaya St, Moscow, Moscow 109240, RU |
| Phone | +7 495 726-52-53 |
| Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology, Manufacturing General, Drug Discovery, Manufacturing, Science and Engineering, Pharmaceutical, Health Care |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Infectex employee's phone or email?
Infectex Questions
The Infectex annual revenue was $1 million in 2024.
Infectex is based in Moscow, Moscow.
The NAICS codes for Infectex are [3254, 32541, 32, 325].
The SIC codes for Infectex are [28, 283].
Related Companies
